Clinical Trials

Muscle Invasive Bladder Urothelial Carcinoma

NCT06524544 2026-04-15

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Carcinoma, Transitional Cell

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT04628767 2026-04-14

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04071236 2026-04-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05691465 2026-04-13

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

30 enrolled

Prostatic Neoplasms

NCT06022822 2026-04-13

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

90 enrolled

Prostate Adenocarcinoma

NCT06439836 2026-04-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1 Recruiting

27 enrolled

Carcinoma, Transitional Cell

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

39 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Prostatic Neoplasms

NCT06995898 2026-04-13

The Vanguard Study: Testing a New Way to Screen for Cancer

Phase NA Recruiting

24,000 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT05327686 2026-04-08

SAMURAI

240 enrolled

Carcinoma, Renal Cell

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Urinary Bladder Neoplasms

NCT04981509 2026-04-07

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06389786 2026-04-06

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Phase NA Recruiting

50 enrolled

Prostatic Neoplasms

NCT05946213 2026-04-03

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

1,209 enrolled

Prostatic Neoplasms

NCT06526299 2026-03-24

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

51 enrolled

DermatologicGenitourinary

Prostatic Neoplasms

NCT06391099 2026-03-19

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Phase NA Recruiting

60 enrolled

Carcinoma, Renal Cell, Melanoma

NCT04788277 2026-03-13

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

Recruiting

675 enrolled

Prostatic Neoplasms

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

40 enrolled

Prostatic Neoplasms

NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

30 enrolled

Prostatic Neoplasms

NCT04706481 2026-03-12

Archival of Human Biological Samples in CU-Med Biobank

Recruiting

10,000 enrolled

Diabetes Mellitus, Disease, Heart Diseases, Kidney Diseases, Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06349642 2026-03-12

ELEPHAS-04

Recruiting

324 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07164027 2026-03-10

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Phase EARLY_PHASE1 Recruiting

30 enrolled

Prostatic Neoplasms

NCT06330805 2026-03-09

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT06432036 2026-03-06

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

25 enrolled

Phase EARLY_PHASE1 Recruiting

Carcinoma, Renal Cell

NCT05045066 2026-03-02

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

220 enrolled

Prostatic Neoplasms

NCT07128680 2026-02-27

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Phase 1 Recruiting

33 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Wilms Tumor

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors